Evidence map›Paper›PMID 36413568›Full record

ArticlePloS one2022

Monoallelic variants resulting in substitutions of MAB21L1 Arg51 Cause Aniridia and microphthalmia.

Hildegard Nikki Hall, Hemant Bengani, Robert B Hufnagel, Giuseppe Damante, Morad Ansari, Joseph A Marsh, Graeme R Grimes, Alex von Kriegsheim, David Moore, Lisa McKie and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Hildegard Nikki HallMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-7082-1523
Hemant BenganiMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Robert B HufnagelNational Eye Institute, National Institutes of Health, Bethesda, MD, United States of America.
Giuseppe DamanteDepartment of Medicine, University of Udine, Udine, Italy.
Morad AnsariSouth East Scotland Genetic Service, Western General Hospital, Edinburgh, United Kingdom.
Joseph A MarshMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4132-0628
Graeme R GrimesMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Alex von KriegsheimMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
David MooreSouth East Scotland Genetic Service, Western General Hospital, Edinburgh, United Kingdom.
Lisa McKieMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Jamalia RahmatOphthalmology Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Catia MioDepartment of Medicine, University of Udine, Udine, Italy.
Moira BlythUniversity of Leeds, St. James's University Hospital, Leeds, United Kingdom.
Wee Teik KengDepartment of Genetics, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia.
Lily IslamWest Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, England.
Meriel McEntargartMedical Genetics, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Marcel M MannensGenome Diagnostics laboratory, Department of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Veronica Van HeyningenMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-0359-0141
Joe RaingerRoslin Institute, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-1091-5100
Brian P BrooksNational Eye Institute, National Institutes of Health, Bethesda, MD, United States of America.
David R FitzPatrickMRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4861-969X
Institute of Genetics and Cancer · GBHospital Kuala Lumpur · MYNational Institutes of Health · USUniversity of Udine · ITWestern General Hospital · GBAmsterdam University Medical Centers · NLBirmingham Women’s and Children’s NHS Foundation Trust · GBRoslin Institute · GBSt George’s University Hospitals NHS Foundation Trust · GBUniversity of Leeds · GB

Funding

Medical Research Council MC_UU_00007/3Medical Research Council MR/S033165/1Wellcome TrustWellcome Trust 205171_Z_16_ZWellcome Trust WT091310
6 · The paper itself

Abstract

Classical aniridia is a congenital and progressive panocular disorder almost exclusively caused by heterozygous loss-of-function variants at the PAX6 locus. We report nine individuals from five families with severe aniridia and/or microphthalmia (with no detectable PAX6 mutation) with ultrarare monoallelic missense variants altering the Arg51 codon of MAB21L1. These mutations occurred de novo in 3/5 families, with the remaining families being compatible with autosomal dominant inheritance. Mice engineered to carry the p.Arg51Leu change showed a highly-penetrant optic disc anomaly in heterozygous animals with severe microphthalmia in homozygotes. Substitutions of the same codon (Arg51) in MAB21L2, a close homolog of MAB21L1, cause severe ocular and skeletal malformations in humans and mice. The predicted nucleotidyltransferase function of MAB21L1 could not be demonstrated using purified protein with a variety of nucleotide substrates and oligonucleotide activators. Induced expression of GFP-tagged wildtype and mutant MAB21L1 in human cells caused only modest transcriptional changes. Mass spectrometry of immunoprecipitated protein revealed that both mutant and wildtype MAB21L1 associate with transcription factors that are known regulators of PAX6 (MEIS1, MEIS2 and PBX1) and with poly(A) RNA binding proteins. Arg51 substitutions reduce the association of wild-type MAB21L1 with TBL1XR1, a component of the NCoR complex. We found limited evidence for mutation-specific interactions with MSI2/Musashi-2, an RNA-binding proteins with effects on many different developmental pathways. Given that biallelic loss-of-function variants in MAB21L1 result in a milder eye phenotype we suggest that Arg51-altering monoallelic variants most plausibly perturb eye development via a gain-of-function mechanism.

Indexed as

AniridiaMicrophthalmosAnimalsEye ProteinsHeterozygoteHomeodomain ProteinsHumansIntracellular Signaling Peptides and ProteinsMiceMutation, MissensePAX6 Transcription FactorRNA-Binding ProteinsTranscription FactorsEye ProteinsHomeodomain ProteinsIntracellular Signaling Peptides and ProteinsMAB21L1 protein, humanMAB21L2 protein, humanMab21l2 protein, mouseMSI2 protein, humanPAX6 Transcription FactorRNA-Binding ProteinsTranscription Factors

Identifiers

PMID36413568
PMCPMC9681113
OpenAlexW4309600450

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.